Form 4: Voyager Therapeutics Director Granted Stock Options

Voyager Therapeutics reports the grant of stock options to Director George A. Scangos under the company's 2025 Stock Incentive Plan.

Summary

• George A. Scangos, a Director at Voyager Therapeutics, Inc., was granted 30,000 stock options.
• The options have an exercise price of $3.43 per share.
• The grant date was June 9, 2026, with an exercise date of June 9, 2036.
• These options are part of the company's 2025 Stock Incentive Plan and vest over one year from the grant date or by the next annual meeting, contingent on continued service.
• The filing also includes a Power of Attorney document authorizing representatives to handle SEC filings on behalf of Mr. Scangos.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details a standard compensation event (stock option grant) for a director and a procedural filing (Power of Attorney), rather than significant financial results or strategic shifts.

Positives

• Director George A. Scangos has been granted stock options, aligning his interests with the company's performance.
• The stock options are granted under the 2025 Stock Incentive Plan, indicating a structured approach to executive compensation.
• The vesting schedule is tied to continued service and a specific timeframe, providing incentives for long-term commitment.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Voyager Therapeutics.
• Continued service as a director is a condition for vesting, meaning any departure before the vesting date would forfeit the options.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the director's continued service, with vesting occurring over the next year or by the next annual meeting.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align executive interests with shareholder value, especially for companies focused on long-term development and clinical trials.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aligns incentives, potentially benefiting shareholders if the company's stock price increases.
• Employees: Indirectly impacted by the company's performance, which the director's incentives are tied to.
• Management: The filing is a routine disclosure related to executive compensation and governance.

Next Steps

• George A. Scangos will continue his service as a director, subject to the vesting conditions of the stock options.
• The authorized attorneys-in-fact will manage SEC filings on behalf of George A. Scangos.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Form 4, Stock Options, Director Compensation, SEC Filing, Insider Trading, Equity Incentive Plan, George A. Scangos